{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:20:32Z","timestamp":1790036432387,"version":"4.0.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.antiviral.2017.02.008","type":"journal-article","created":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T01:30:24Z","timestamp":1487640624000},"page":"116-123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["A screening assay for the identification of host cell requirements and antiviral targets for hepatitis D virus infection"],"prefix":"10.1016","volume":"141","author":[{"given":"Bettina","family":"Buchmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katinka","family":"D\u00f6hner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schirdewahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Sodeik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Manns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Ciesek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"von Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2017.02.008_bib1","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/cm.20472","article-title":"Rho-kinase\/ROCK: a key regulator of the cytoskeleton and cell polarity","volume":"67","author":"Amano","year":"2010","journal-title":"Cytoskelet. Hob."},{"key":"10.1016\/j.antiviral.2017.02.008_bib2","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/j.1476-5381.1989.tb12652.x","article-title":"Vasodilator actions of HA1077 in\u00a0vitro and in\u00a0vivo putatively mediated by the inhibition of protein kinase","volume":"98","author":"Asano","year":"1989","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.antiviral.2017.02.008_bib3","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2016.04.016","article-title":"Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib\/IIa study","volume":"65","author":"Bogomolov","year":"2016","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.antiviral.2017.02.008_bib4","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1172\/JCI17704","article-title":"In\u00a0vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus","volume":"112","author":"Bordier","year":"2003","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.antiviral.2017.02.008_bib5","doi-asserted-by":"crossref","first-page":"R100","DOI":"10.1186\/gb-2006-7-10-r100","article-title":"CellProfiler: image analysis software for identifying and quantifying cell phenotypes","volume":"7","author":"Carpenter","year":"2006","journal-title":"Genome Biol."},{"key":"10.1016\/j.antiviral.2017.02.008_bib6","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1128\/JVI.72.6.4783-4788.1998","article-title":"Initiation of hepatitis delta virus genome replication","volume":"72","author":"Dingle","year":"1998","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2017.02.008_bib7","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1021\/cb400789e","article-title":"The commonly used PI3-kinase probe LY294002 is an inhibitor of BET bromodomains","volume":"9","author":"Dittmann","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.antiviral.2017.02.008_bib8","series-title":"News Release March 26, 2007","author":"Eisai Co. Ltd","year":"2007"},{"key":"10.1016\/j.antiviral.2017.02.008_bib9","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1093\/infdis\/155.5.931","article-title":"Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B","volume":"155","author":"Fattovich","year":"1987","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.antiviral.2017.02.008_bib10","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/gut.46.3.420","article-title":"Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B","volume":"46","author":"Fattovich","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.antiviral.2017.02.008_bib11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.virol.2009.02.007","article-title":"The hepatitis delta virus RNA genome interacts with the human RNA polymerases I and III","volume":"386","author":"Greco-Stewart","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2017.02.008_bib12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hep.27102","article-title":"Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta","volume":"60","author":"Heidrich","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2017.02.008_bib13","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1261\/rna.034744.112","article-title":"Activation of PKR by RNA misfolding: HDV ribozyme dimers activate PKR","volume":"18","author":"Heinicke","year":"2012","journal-title":"RNA"},{"key":"10.1016\/j.antiviral.2017.02.008_bib14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(10)61931-9","article-title":"Hepatitis delta virus","volume":"378","author":"Hughes","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2017.02.008_bib15","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1006\/viro.1993.1201","article-title":"A\u00a0unique conformation at the carboxyl terminus of the small hepatitis delta antigen revealed by a specific monoclonal antibody","volume":"193","author":"Hwang","year":"1993","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2017.02.008_bib16","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/hr.2015.33","article-title":"Intravenous fasudil improves in-hospital mortality of patients with right heart failure in severe pulmonary hypertension","volume":"38","author":"Jiang","year":"2015","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.antiviral.2017.02.008_bib17","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S1473-3099(15)00074-2","article-title":"Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial","volume":"15","author":"Koh","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2017.02.008_bib18","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1128\/JVI.62.12.4439-4444.1988","article-title":"Characterization of self-cleaving RNA sequences on the genome and antigenome of human hepatitis delta virus","volume":"62","author":"Kuo","year":"1988","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2017.02.008_bib19","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1128\/JVI.63.5.1945-1950.1989","article-title":"Initiation of replication of the human hepatitis delta virus genome from cloned DNA: role of delta antigen","volume":"63","author":"Kuo","year":"1989","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2017.02.008_bib20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1099\/0022-1317-80-1-91","article-title":"Localization of isoprenylated antigen of hepatitis delta virus by anti-farnesyl antibodies","volume":"80","author":"Lin","year":"1999","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.antiviral.2017.02.008_bib21","doi-asserted-by":"crossref","first-page":"12237","DOI":"10.1128\/JVI.01218-12","article-title":"Cyclin-dependent kinase 2 phosphorylates s\/t-p sites in the hepadnavirus core protein C-terminal domain and is incorporated into viral capsids","volume":"86","author":"Ludgate","year":"2012","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2017.02.008_bib22","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nm.2341","article-title":"EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy","volume":"17","author":"Lupberger","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2017.02.008_bib23","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/hep.24758","article-title":"Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation","volume":"55","author":"L\u00fctgehetmann","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2017.02.008_bib24","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1128\/JVI.76.8.3920-3927.2002","article-title":"Rolling circle replication of hepatitis delta virus RNA is carried out by two different cellular RNA polymerases","volume":"76","author":"Macnaughton","year":"2002","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2017.02.008_bib25","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2017.02.008_bib26","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1203\/PDR.0b013e31821b581c","article-title":"The farnesyltransferase inhibitors Tipifarnib and Lonafarnib inhibit cytokines secretion in a cellular model of mevalonate kinase deficiency","volume":"70","author":"Marcuzzi","year":"2011","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.antiviral.2017.02.008_bib27","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1146\/annurev.cellbio.13.1.261","article-title":"Cyclin-dependent kinases: engines, clocks, and microprocessors","volume":"13","author":"Morgan","year":"1997","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.antiviral.2017.02.008_bib28","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1517\/13543784.15.6.709","article-title":"Lonafarnib in cancer therapy","volume":"15","author":"Morgillo","year":"2006","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.antiviral.2017.02.008_bib29","doi-asserted-by":"crossref","first-page":"10540","DOI":"10.1128\/JVI.73.12.10540-10545.1999","article-title":"Characterization of the phosphorylated forms and the phosphorylated residues of hepatitis delta virus delta antigens","volume":"73","author":"Mu","year":"1999","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2017.02.008_bib30","first-page":"3858","article-title":"Growth of human hepatoma cell lines with differentiated functions in chemically defined medium","volume":"42","author":"Nakabayashi","year":"1982","journal-title":"Cancer Res."},{"key":"10.1016\/j.antiviral.2017.02.008_bib31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrm2822","article-title":"The nuts and bolts of AGC protein kinases","volume":"11","author":"Pearce","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.antiviral.2017.02.008_bib32","first-page":"1","article-title":"Primary biliary acids inhibit hepatitis D virus (HDV) entry into human hepatoma cells expressing the sodium-taurocholate cotransporting polypeptide (NTCP)","volume":"10","author":"Pereira","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2017.02.008_bib33","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nbt1389","article-title":"Prevention of hepatitis B virus infection in\u00a0vivo by entry inhibitors derived from the large envelope protein","volume":"26","author":"Petersen","year":"2008","journal-title":"Nat. Biotech."},{"key":"10.1016\/j.antiviral.2017.02.008_bib34","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.antiviral.2017.02.008_bib35","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1006\/viro.1997.8644","article-title":"Geographic distribution and genetic variability of hepatitis delta virus genotype I","volume":"234","author":"Shakil","year":"1997","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2017.02.008_bib36","doi-asserted-by":"crossref","first-page":"794","DOI":"10.5059\/yukigoseikyokaishi.54.794","article-title":"Development of fasudil hydrochloride (Eril\u00ae): a new protein kinase inhibitor","volume":"54","author":"Sone","year":"1996","journal-title":"J.\u00a0Synth. Org. Chem. Jpn."},{"key":"10.1016\/j.antiviral.2017.02.008_bib37","series-title":"Hepatocytes - Methods in Molecular Biology","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/978-1-60761-688-7_25","article-title":"The use of hepatocytes to investigate HDV infection: the HDV\/HepaRG model","author":"Sureau","year":"2010"},{"key":"10.1016\/j.antiviral.2017.02.008_bib38","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1469-7793.2000.0033m.x","article-title":"Inhibition of Rho-associated kinase blocks agonist-induced Ca2+ sensitization of myosin phosphorylation and force in Guinea-pig ileum","volume":"522","author":"Sw\u00e4rd","year":"2000","journal-title":"J.\u00a0Physiol."},{"key":"10.1016\/j.antiviral.2017.02.008_bib39","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nrmicro2574","article-title":"Subversion of the actin cytoskeleton during viral infection","volume":"9","author":"Taylor","year":"2011","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.antiviral.2017.02.008_bib40","doi-asserted-by":"crossref","first-page":"e28318","DOI":"10.4161\/sgtp.28318","article-title":"Rho\u2019ing in and out of cells","volume":"5","author":"Van den Broeke","year":"2014","journal-title":"Small GTPases"},{"key":"10.1016\/j.antiviral.2017.02.008_bib41","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jhep.2012.12.008","article-title":"The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus","volume":"58","author":"Volz","year":"2016","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.antiviral.2017.02.008_bib42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1371\/journal.pone.0024142","article-title":"The novel immunosuppressive protein kinase C inhibitor sotrastaurin has no pro-viral effects on the replication cycle of hepatitis B or C virus","volume":"6","author":"von Hahn","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2017.02.008_bib43","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/323508a0","article-title":"Structure, sequence and expression of the hepatitis delta (D) viral genome","volume":"323","author":"Wang","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2017.02.008_bib44","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa0912696","article-title":"Peginterferon plus adefovir versus either drug alone for hepatitis delta","volume":"364","author":"Wedemeyer","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.antiviral.2017.02.008_bib45","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrgastro.2009.205","article-title":"Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead","volume":"7","author":"Wedemeyer","year":"2010","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2017.02.008_bib46","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1128\/JVI.62.2.594-599.1988","article-title":"A\u00a0single antigenomic open reading frame of the hepatitis delta virus encodes the epitope(s) of both hepatitis delta antigen polypeptides p24 delta and p27 delta","volume":"62","author":"Weiner","year":"1988","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2017.02.008_bib47","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1073\/pnas.86.6.1831","article-title":"Human hepatitis delta virus RNA subfragments contain an autocleavage activity","volume":"86","author":"Wu","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2017.02.008_bib48","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/hep.1840160504","article-title":"Expression and localization of the small and large delta antigens during the replication cycle of hepatitis D virus","volume":"16","author":"Wu","year":"1992","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2017.02.008_bib49","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.1057925","article-title":"Stimulation of RNA polymerase II elongation by hepatitis delta antigen","volume":"293","author":"Yamaguchi","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2017.02.008_bib50","doi-asserted-by":"crossref","first-page":"e00049","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"Elife"},{"key":"10.1016\/j.antiviral.2017.02.008_bib51","doi-asserted-by":"crossref","first-page":"6190","DOI":"10.1128\/JVI.70.9.6190-6198.1996","article-title":"Casein kinase II and protein kinase C modulate hepatitis delta virus RNA replication but not empty viral particle assembly","volume":"70","author":"Yeh","year":"1996","journal-title":"J.\u00a0Virol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216306738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216306738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T15:19:29Z","timestamp":1601651969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354216306738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":51,"alternative-id":["S0166354216306738"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2017.02.008","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A screening assay for the identification of host cell requirements and antiviral targets for hepatitis D virus infection","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2017.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}